Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;67(1):81-88.
doi: 10.1111/1754-9485.13487. Epub 2022 Oct 27.

Time to resolution of iodine-123 metaiodobenzylguanidine (123 I-MIBG) avidity and local control outcomes for high-risk neuroblastoma following radiation therapy

Justin Oh  1 , Paulina Gutkin  1 , Yi Peng Wang  1 , Navjot Sandhu  1 , Robbie G Majzner  2 , Helen Nadel  3 , Hiroyuki Shimada  4 , Olivia Lansinger  1 , Rie von Eyben  1 , Sarah Donaldson  1 , Matias Bruzoni  5 , Quaovi H Sodji  1 , Susan M Hiniker  1
Affiliations

Time to resolution of iodine-123 metaiodobenzylguanidine (123 I-MIBG) avidity and local control outcomes for high-risk neuroblastoma following radiation therapy

Justin Oh et al. J Med Imaging Radiat Oncol. 2023 Feb.

Abstract

Introduction: 123 I-MIBG scan is used in neuroblastoma (NB) to monitor treatment response. Time to resolution of 123 I-MIBG avidity after radiation therapy (RT) is unknown. We sought to determine time to resolution of 123 I-MIBG avidity after RT and local failure (LF) rate.

Methods: We performed a retrospective review of children with high-risk NB who underwent 123 I-MIBG scans pre- and post-RT from 2003 to 2019. Time from RT to resolution of 123 I-MIBG activity was analysed. LF and cumulative incidence of local progression (CILP) after RT stratified by site, presence of residual disease and use of boost RT were determined.

Results: Forty-two patients with median age 3.9 years (1.9-4.7 years) were included, with median follow-up time 3.9 years (1.4-6.9). Eighty-six lesions were treated with RT to median dose of 21.6 Gy. Eighteen of 86 lesions were evaluable for time to resolution of MIBG avidity after RT, with median resolution time of 78 days (36-208). No LF occurred among 26 patients who received RT to primary sites after GTR, versus 4/12 (25%) patients treated with residual primary disease. 2-year CILP was 19% (12% primary disease 25% metastatic disease (P = 0.18)). 2-year CILP for non-residual primary, residual primary, non-residual metastatic and residual metastatic lesions was 0%, 42%, 11% and 30% respectively (P = 0.01) and for boosted and non-boosted residual lesions was 29% and 35% (P = 0.44).

Conclusion: Median time to MIBG resolution after RT was 78 days. Primary lesions without residual disease had excellent local control. LF rate was higher after RT for residual disease, with no benefit for boost RT.

Keywords: nuclear medicine; radiation oncology; radiation oncology imaging.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol 2010; 37: 662-79.
    1. Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg 2019; 28: 150859.
    1. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016; 36: 258-78.
    1. Matthay KK, Edeline V, Lumbroso J et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486-91.
    1. Liu KX, Naranjo A, Zhang FF et al. Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the Children's oncology group ANBL0532 study. J Clin Oncol 2020; 38: 2741-52.

LinkOut - more resources